⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361286 | 1.00 | — | — | |
| SCHEMBL1361284 | 1.00 | — | — | |
| SCHEMBL5110324 | 0.84 | — | — | |
| SCHEMBL10489206 | 0.82 | — | — | |
| SCHEMBL10358248 | 0.79 | — | — | |
| SCHEMBL8776762 | 0.78 | — | — | |
| SCHEMBL821097 | 0.78 | — | — | |
| SCHEMBL21457914 | 0.78 | — | — | |
| SCHEMBL11348176 | 0.78 | — | — | |
| SCHEMBL11348174 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114616226-B | Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders | TMEM16A有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-117683042-A | Fused tetracyclic compound, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| WO-2022138893-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION BATTERY | ＭＵアイオニックソリューションズ株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-114616226-A | Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders | TMEM16A有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-108112251-B | NRF2 modulators | 葛兰素史克知识产权发展有限公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| CN-108147700-B | Preparation method of shrinkage-reducing viscosity-reducing polycarboxylic acid plasticizer | 科之杰新材料集团有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| WO-2004101631-A2 | METHOD FOR PRODUCING CARBOXYL-TERMINATED POLYISOBUTENES | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-25 | — | — | WO | disclosed |
| US-20040215033-A1 | Preparation of silyl ketene acetal and disilyl ketene acetal | SHIN-ETSU CHEMICAL CO. LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1471069-A1 | Preparation of silyl ketene acetals and disilyl ketene acetals | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
| EP-0293871-B1 | LIGHT STABILIZED, STARSHAPED MICROPARTICLES | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| US-4880859-A | GROUP TRANSFER POLYMERIZATION, COATINGS | CIBA-GEIGY CORPORATION (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0293871-A2 | Light stabilized, starshaped microparticles | CIBA-GEIGY AG (CH) | 1988-12-07 | — | — | EP | disclosed |